Abstract
Bariatric surgery is the most effective treatment option for patients with refractory morbid obesity to help facilitate weight-loss and reduce long-term metabolic morbidity and mortality. Over 200,000 procedures are performed annually in the United States with sleeve gastrectomy being the most common surgical approach. However, the growing popularity of surgical bariatric interventions has led to an increase in incidental findings of gastrointestinal neoplasms in intraoperative specimens. We report our experience performing a robotic sleeve gastrectomy in a 58-year-old woman who was later found to have a gastrointestinal stromal tumor (GIST) with positive immunohistochemical marking.